• Study on the Effects of IO102 Hydrochloride and IO103 Acetate for Patients with Head and Neck Cancer

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on the Safety and Effectiveness of VIR-2218, VIR-3434, and Peginterferon Alfa-2a for Patients with Chronic Hepatitis B

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Romania

  • Study of Pembrolizumab with Lenvatinib after Chemoradiation Treatment in Patients with Locally Advanced Head and Neck Cancer who are PD-L1 Positive

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany

  • Study on Enzalutamide for Patients with Localized Prostate Cancer Undergoing Robotic-Assisted Surgery

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Effects of Paltusotine for Patients with Untreated Acromegaly

    Not recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria France Germany Greece Hungary Italy +1

  • Study on the Effects of Loratadine and Rapamycin for Patients with Lymphangioleiomyomatosis (LAM)

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of MEN1611 and Eribulin for Advanced Metaplastic Breast Cancer in Patients with PIK3CA/PTEN Alterations

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of emapalumab in children and adults with Macrophage Activation Syndrome (MAS) occurring in Still’s Disease or Systemic Lupus Erythematosus

    Not recruiting

    4 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Italy The Netherlands

  • Study on the Safety and Efficacy of CLS12311 and Autologous Red Blood Cells for Patients with Relapsing Remitting Multiple Sclerosis

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Czechia Germany Italy

  • Study on the Safety and Effectiveness of Acasunlimab and Pembrolizumab for Patients with Recurrent Non-Small Cell Lung Cancer

    Not recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Italy The Netherlands Poland Portugal +1

powered by